Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Nov 19, 2017
Dividend Increases/Decreases for the Week Ending November 17
Let's take a look at companies raising/lowering their dividends this week. Nov 17, 2017
How Have Our Best “Dividend Growth Ideas” Performed During 2017?
We wrote recently about how well the top-weighted ideas in the Best Ideas Newsletter portfolio have performed during 2017, but what about the top-weighted ideas in the other newsletter portfolio, the Dividend Growth Newsletter portfolio? How have they performed during 2017? Please tell us you know how well the top-weighted ideas have been performing. Nov 17, 2017
Celgene Implodes
The pharma/biotech industry operates in a boom-bust environment where the market cap of a company can post a meteoric rise or suffer a precipitous fall based on the data published from recently completed clinical trials. The industry remains one of the most innovative fields, but the quest for new products leads to constant disruption and a subsequent spike in volatility. Of late, the volatility pendulum for Celgene has swung in favor of the bears with the company posting a costly phase 3 failure. Nov 16, 2017
Cisco’s Shares Are Surging!
Image Source: Cisco. We received some fantastic news from newsletter portfolio idea Cisco. Shares are surging! Please tell me you knew that Cisco was one of our favorite ideas. Nov 15, 2017
Buffalo Wild Wings Should Go Private and Hasbro Should Buy Mattel…But at the Right Price
Image Source: Hasbro. There is a lot happening across the M&A landscape as of late. Buffalo Wild Wings has reportedly received a go-private offer, while speculation is swirling that Hasbro is looking to gobble up Mattel. We like the prospects of both scenarios. However, price will always matter. Buffalo Wild Wings should hold out for the very best offer, while Hasbro should be very careful not to overpay for assets that may be past their prime. Nov 14, 2017
How Have Our “Best Ideas” Performed During 2017?
The top-weighted ideas are getting the job done, while we avoided one of the biggest missteps in all of 2017. We’ve had better years, but 2017 was still a great one. Nov 14, 2017
GE Takes the Plunge, Halves Dividend
There may have been little surprise across the market when GE halved its dividend in its investor update November 13, but shares are selling off after management issued weaker-than-expected EPS guidance for 2018. Nov 13, 2017
A Guide to Using Valuentum's Stock Reports
There is no better value in investment research and analysis. Period. Within the individual premium plan, we offer two newsletters (the Best Ideas Newsletter, Dividend Growth Newsletter), delivered by email. On the website, we provide hundreds of stock and dividend reports, proprietary metrics such as the Dividend Cushion ratio, fair value estimates, Valuentum Buying Index ratings, commentary and analysis, weekly screens, plus access to the Valuentum team and much more. As a member, learn more about Valuentum's stock reports by downloading the guide here (pdf). Thank you! Nov 11, 2017
4 Burning Questions About Gilead Sciences
Image Source: Gilead. We were pleased with the jump in shares of Gilead Sciences following its recent addition to the newsletter portfolios. The equity has given back some of those gains more recently as questions have resurfaced on the vitality of the enterprise. In this article, we work through the top 4 questions for readers to consider in evaluating Gilead Sciences. Nov 10, 2017
Could Sally Beauty Become Amazon’s “Whole Foods” Foray into Beauty Supply?
Image Source: Sally Beauty. “The Amazon Effect” on traditional retail is not a new development, but there are some pockets of retail that were believed to be impenetrable by the e-commerce giant. We’re beginning to see that such a notion may have been nothing short of wishful thinking.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492493494495496497498499500 501502503504505506507508509510511512513514515516517518519520 521522523524525526527528529530531532533534535536537538539540 541542543544545546547548549550551552next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|